Ayala Pharmaceuticals Inc. - Company Profile
Powered by 
All the data and insights you need on Ayala Pharmaceuticals Inc. in one report.
$295
- Save hours of research time and resources with
our up-to-date Ayala Pharmaceuticals Inc. Strategy Report
- Understand Ayala Pharmaceuticals Inc. position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Ayala Pharmaceuticals Inc. (Ayala) formerly Advaxis Inc (Advaxis) is a biotechnology company that focuses on the discovery, development, and commercialization of multiple cancer immunotherapies. The company develops immunotherapies based on its proprietary Lm Technology, an antigen delivery platform that activates the immune system naturally. The Lm technology uses bioengineered live attenuated Listeria monocytogenes (Lm) bacteria to stimulate cancer-fighting T cells directed against a cancer antigen. Its immunotherapy candidates are intended for the treatment of neoantigen-directed therapies, prostate cancer, and human papilloma virus-associated cancers. The company has partnerships with various biopharmaceutical companies to develop and commercialize proprietary cancer immunotherapies. Ayala is headquartered in Princeton, New Jersey, the US.
Headquarters
United States of America
Address
9 Deer Park Drive, Suite K-1, Monmouth Junction, New Jersey, 08852
Website
ayalapharma.com
Telephone
1 732 5451590
No of Employees
14
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ADXS (OTC)
Revenue (2021)
$250,000
-92.3%
(2021 vs 2020)
EPS
XYZ
Net Income (2021)
XYZ
19.6%
(2021 vs 2020)
Market Cap*
$23.7M
Net Profit Margin (2021)
XYZ
-941.8%
(2021 vs 2020)
* As of and is in US$
Ayala Pharmaceuticals Inc. premium industry data and analytics
Products and Services
| Products |
|---|
| ADXS-PSA: |
| Prostate Cancer |
| ADXS-HER2: |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Acquisitions/Mergers/Takeovers | In October, the company merged with Biosight, Ltd. |
| 2023 | Acquisitions/Mergers/Takeovers | In January, the company merged with Ayala Pharmaceuticals. |
| 2023 | Acquisitions/Mergers/Takeovers | In January, the company merged with Advaxis, a biotechnology company. |
Competitor Comparison
| Key Parameters | Ayala Pharmaceuticals Inc. | Amicus Therapeutics Inc | Agenus Inc | Celldex Therapeutics Inc | bluebird bio Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Monmouth Junction | Philadelphia | Lexington | Hampton | Somerville |
| State/Province | New Jersey | Pennsylvania | Massachusetts | New Jersey | Massachusetts |
| No. of Employees | 14 | 517 | 389 | 160 | 323 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| David Sidransky | Chairman | Executive Board | 2013 | 62 |
| Kenneth A. Berlin | Director; President; Chief Executive Officer | Executive Board | 2018 | 58 |
| Andres A. Gutierrez | Chief Medical Officer; Executive Vice President | Senior Management | 2018 | 62 |
| Shmuel Tuvia, Ph.D. | Chief Scientific Officer | Senior Management | - | - |
| Dana Gelbaum | General Manager; Chief Business Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer